SCD and hepatocellular carcinoma: To further explore whether the role of URI-SCD1 in sorafenib resistance is clinically relevant, the expression of URI and SCD1 was examined in a cohort of HCC patients received adjuvant sorafenib treatment (cohort B) (Supplementary Fig. 11a and Supplementary Data 5).